

AUD \$3.7M Income Tax Refund Received

SYDNEY Australia, 1 July 2026: Recce Pharmaceuticals Ltd (**ASX: RCE, FSE: R9Q**) (the **Company**), the Company developing a new class of Synthetic Anti-infectives, is pleased to announce receipt of an AUD \$3,667,427 income tax refund from the Australian Taxation Office (ATO) for the financial year ending 30 June 2025.

The refund is comprised of the Company's overseas R&D's expenditure of AUD \$3,571,600 and an additional AUD \$95,826 in interest, paid by the ATO in respect of the FY2025 period.

The Company expects the receipt of further non-dilutive funds and capital raise proceeds, which extends Recce's pro-forma cash position of AUD ~\$33.1 million¹ (previously \$29.5 million), remaining well placed to achieve upcoming Phase 3 clinical trial milestones. Furthermore, the Company is looking to receive an R&D Tax Incentive rebate from the ATO for the financial year ending 30 June 2026 in the amount of AUD ~\$7.5 million. The income tax refund complements the Company's recently completed placement to institutional, sophisticated and professional investors, raising approximately AUD \$4.0 million, with a Share Purchase Plan (SPP) opening to eligible shareholders on 6 July 2026 to raise up to an additional AUD \$4.0 million. Further details of the equity raising were announced to ASX on 26 June 2026.

This announcement has been approved for release by Recce Pharmaceuticals Board.

¹ Includes proceeds from Capital Raise (before offer costs) and if debt component is drawn (subject to certain time limitations and the satisfaction of certain conditions)



About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.